Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced the receipt of patent approval in the United States for its proprietary core technology, the fully human antibody mice platform RenMab. This U.S. patent award comes on the heels of a similar award in China earlier this year.
Biocytogen utilizes its independently developed Size-Unlimited and Precise Chromosome Engineering (SUPCE) technology to genetically engineer mice with in situ replaced full human antibody heavy and light chain variable regions, resulting in the RenMab mice. These mice possess the complete human antibody heavy VDJ and light VJ genes, enabling the generation of fully human antibodies with maximum diversity. This approach enhances the success rate of antibody discovery and eliminates the need for in vitro humanization, thereby reducing the risks associated with antibody development and saving time and costs for drug developers. The platform’s success is evident in its numerous partnerships with leading pharmaceutical companies, including Merck KGaA, Janssen, Xencor, BeiGene, Innovent, Junshi Biosciences, and Remegen.- Flcube.com
